Drug treatments for obesity/Bibliography: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Rachael Kirkbride
imported>Rachael Kirkbride
Line 10: Line 10:
==Primary Research Papers==
==Primary Research Papers==


1. Rossner S, Sjostrom L, Noack R, Meinders A, Noseda G.(2000). Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. ''Obesity Research''.8:41-61  ''"Orlistat administered for 2 years promotes weight loss and minimizes weight regain. Additionally, orlistat therapy improves lipid profile, blood pressure, and quality of life."''
1. Rossner S, Sjostrom L, Noack R, Meinders A, Noseda G. (2000). Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. ''Obesity Research''.8:41-61  ''"Orlistat administered for 2 years promotes weight loss and minimizes weight regain. Additionally, orlistat therapy improves lipid profile, blood pressure, and quality of life."''

Revision as of 10:30, 6 October 2009

This article is developed but not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
A list of key readings about Drug treatments for obesity.
Please sort and annotate in a user-friendly manner. For formatting, consider using automated reference wikification.

Review Articles

1. Magni P. et al. (2009) Feeding behavior in mammals including humans. Ann.N.Y.Acad.Sci. 1163:221-232. PMID 19456343

2. Coutinho W. (2009)The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. Arquivos Brasileiros De Endocrinologia E Metabologia. 53:262-270 "The most widely used anti-obesity agents are sibutramine and orlistat, both available in clinical practice for about a decade."

Primary Research Papers

1. Rossner S, Sjostrom L, Noack R, Meinders A, Noseda G. (2000). Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obesity Research.8:41-61 "Orlistat administered for 2 years promotes weight loss and minimizes weight regain. Additionally, orlistat therapy improves lipid profile, blood pressure, and quality of life."